Health (PRISME)

  • Presentation
  • Activities
  • Members
  • Publications

The PRISME team is composed of physicists, biochemists, biologists and radiotherapists. We specialize in multidisciplinary research aimed at developing, optimizing and controlling innovative radiotherapies, whether it be hadrontherapy or therapies using radioactive ion-emitting elements or nanoparticles. These radiotherapies aim to improve the treatment of certain cancers by increasing the effect of ionizing radiation in the tumor while minimizing its harmful effects on healthy tissues.

Our multidisciplinary approach aims to quantify, understand and predict the effect of ionizing radiation on living organisms from processes induced at extremely short times (attosecond) at small scales (atomic nucleus) to long-term consequences (years) at the patient level.
We therefore design and carry out irradiation experiments on targets ranging from molecules or cells to small animals and patient samples (tumor, blood). These experiments feed an important part of our activity which consists in modeling the effects of radiation on living organisms.

One of the innovative techniques of radiotherapy is hadrontherapy, which is to send
an ion beam on the tumors to destroy them. We are working, in particular using simulations, data processing and predictions, to improve these systems by having on-line control over irradiation using dedicated detectors. These tools also have applications in imaging.

The activities can be divided into three research areas:

Axis 1 aims to develop simulations and detectors to control patient irradiation by detecting the particles emitted during hadrontherapy treatment. These developments also offer application prospects in the field of diagnostic imaging.

Axis 2 focuses on the development of multi-scale models and simulations to describe and predict the physical, chemical and biological processes induced by irradiation. It also develops irradiation and dosimetric control means for the measurement of radiobiological effects.

Axis 3 quantifies by experiment the effects induced by irradiation with molecular, cellular, multicellular, in-vitro or in-vivo systems. It focuses on the specificities of innovative radiotherapies and the personalization of care.

PERMANENTS:

NON-PERMANENTS:

- DOCTORANTS / DOCTORAL STUDENTS:

- CHERCHEURS NON-PERMANENTS / NON-PERMANENT RESEARCHERS:
546 documents

  • S. Ferrandon, P. Saultier, J. Carras, P. Battiston-Montagne, N. Hau-Desbat, et al.. Telomere Profiling : Toward Glioblastoma Personalized Medicine. 39th European Radiation Research (ERR2012), Oct 2012, Vietri sul Mare, Italy. ⟨hal-00830922⟩
  • S. Ferrandon, P. Saultier, J. Carras, P. Battiston-Montagne, N.H. Hau-Desbat, et al.. Telomere profiling : toward glioblastoma personalized medicine. 10th International Symposium on Chromosomal Aberrations (ISCA10), Oct 2012, Amalfi, Italy. ⟨hal-00841428⟩
  • G. Bertrand, M. Maalouf, P. Battiston-Montagne, M. Beuve, Clarisse Fournier, et al.. Overcoming the resistance of head and neck squamous cell carcinoma to photon and carbon ion irradiation by targeting cancer stem cells. 39th European Radiation Research (ERR2012), Oct 2012, Vietri sul Mare, Italy. ⟨hal-00830920⟩
  • Julie Constanzo, J. Constanzo, M. Fallavier, G. Alphonse, C. Bernard, et al.. RADIOGRAAFF, A PROTON IRRADIATION FACILITY FOR RADIOBIOLOGICAL STUDIES AT A 4MV VAN DE GRAAFF ACCELERATOR. 39th European Radiation Research (ERR2012), Oct 2012, Vietri sul Mare, Italy. ⟨hal-00830926⟩
  • S. Ferrandon, P. Saultier, J. Carras, P. Battiston-Montagne, G. Alphonse, et al.. Telomere profiling : toward glioblastoma personalized medicine. The EMBO Telomeres and the DDR Meeting, Oct 2012, Isles sur Sorgues, France. ⟨hal-00842488⟩
  • L. Chollier. Modélisation biophysique de l'interaction des ions de hautes énergies avec la matière vivante : application aux traitements de tumeurs par hadronthérapie. 2012. ⟨hal-00949681⟩
  • D. Poncet, S. Ferrandon, P. Saultier, J. Carras, P. Battiston-Montagne, et al.. Statut télomérique : vers un traitement personnalisé du glioblastome. Journées d'automne de l'ANPMCB, Sep 2012, Lyon, France. ⟨hal-00841305⟩
  • Marie-Hélène Richard. Design study of a Compton camera for prompts-gamma imaging during ion beam therapy. Other [cond-mat.other]. Université Claude Bernard - Lyon I, 2012. English. ⟨NNT : 2012LYO10124⟩. ⟨tel-00934715⟩
  • S. Ferrandon, P. Saultier, P. Battiston-Montagne, M. Beuve, G. Alphonse, et al.. Evaluation du statut télomérique comme biomarqueur prédictif de réponse à la radiothérapie de lignées de glioblastome : orientation vers l'Hadronthérapie. 7èmes Journées Scientifiques du Cancéropôle CLARA, Mar 2012, Lyon, France. ⟨hal-00832482⟩
  • G. Alphonse, N.H. Hau, P. Heudel, P. Battiston-Montagne, D. Poncet, et al.. Predictives markers of intrasic radiosensitivity in human glioma cells lines irradiated with photon or carbon ions. 7èmes Journées Scientifiques du Cancéropôle CLARA, Mar 2012, Lyon, France. ⟨hal-00840296⟩

Powered by HAL logo